The Confo® technology platform is protected by a broad patent portfolio, comprising more than 150 patent applications and granted patents in more than 10 patent families worldwide.
Confo Therapeutics holds exclusive worldwide licenses from the Flemish Institute of Biotechnology (VIB) to the basic patents for ConfoBodies® and the ConfoScreen® technology.
In 2019, Confo also obtained an exclusive worldwide license from VIB to the MegaBody™ technology, a novel VHH-based technology for three-dimensional structural analysis of proteins via high-resolution cryo-electron microscopy (cryo-EM).
Confo Therapeutics also has patent protection around its own further developments of the basic ConfoBody technology, such as Confo’s proprietary ConfoSensor® platform for compound screening, compound characterization and target exploration and validation.
